Interview with Julie Austin
1 2021-11-29T19:30:26+00:00 Allison Black a3c87967780b6c76a23a1ddf2a821201d99e4f9a 112 5 Julie Austin is the Executive Director for Community Health at Case Western Reserve University's School of Medicine. plain 2021-11-30T01:17:33+00:00 Allison Black a3c87967780b6c76a23a1ddf2a821201d99e4f9aThis page is referenced by:
-
1
2021-11-16T22:03:35+00:00
Ethical Dilemmas in Nonprofit Healthcare Funding
30
Healthcare nonprofits help cover patients' medical expenses and insurance copayments—but many of these organizations are funded by pharmaceutical companies that manufacture the drugs themselves.
image_header
2021-11-30T04:28:37+00:00
What We Wanted to Know:- How does the donation process work at the Case Western Reserve University School of Medicine?
- Does the School of Medicine do any nonprofit work? If so, what kinds?
- Have there been any instances of stained money or scandals relating to funding at the School of Medicine?
What is a Patient-Assistance Charity?
Patient-assistance charities have become a popular trend in pharmaceutical companies’ efforts to assist patients in paying for their products.
The process follows as drug companies give hundreds of millions of dollars each year to charitable organizations, which in turn provide financial support to cover patients’ prescription co-pays or other medical expenses.Half of America’s 20 largest charities are affiliated with pharmaceutical companies.
What's the Problem?
Controversy arises because pharma-affiliated charities fund co-payments only on prescriptions for drugs that they manufacture.
In 2016, pharmaceutical companies spent approximately $7.4 billion through charities. The co-payment on the price of a drug is typically around 10% of the cost the pharmaceutical company charges to the insurance provider; this means that if $7.4 billion were all spent on covering co-payments, drugmakers could earn $74 billion in revenue.
While pharmaceutical companies argue that helping patients with their co-payments is a way to make medications more accessible, it's entirely their advantage because consumers are only concerned about personal cost.A Citi Research report from 2017 found that every $1 million the pharmaceutical industry spends on charitable donations has the potential to generate nearly $21 million for the sponsor company.
Harming Consumers?
If a pharma-charity offers to cover a patient’s copay expense, the patient will most likely choose the name-brand medication over the cheaper, generic option.
Additionally, pharmaceutical companies broaden their co-payment programs as they continue increasing their drug prices.
The Securities and Exchange Commission (SEC) has been investigating independent charities that are sponsored by pharmaceutical companies. Essentially, these independent organizations use the funding they receive from pharmaceutical firms to cover patients’ copayments; therefore, consumers aren’t aware that pharmaceutical companies are profiting off their payments while increasing the prices of their own medications.
As an example, Andrew Lelling, a US attorney, explains that, “Pfizer knew that the third-party foundation was using Pfizer’s money to cover the co-pays of patients taking Pfizer drugs”...”masking the effect of Pfizer’s price increases.”
Johnson& Johnson, Astellas, Gilead Sciences, Celegne, Biogen among others have faced similar investigations.
Also, pharma-charity contributions are tax-deductible. In the US, companies that give products for the benefit of the “needy or ill” can deduct up to twice the cost of donated goods from their taxes.